Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Completed

• Conditions: Invasive Pneumococcal Disease

• Registration Number: NCT01128439
• Lead Sponsor: Pfizer

Brief Summary

This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.

Detailed Description

No sampling as no subjects are enrolled

Study Timeline

• Study First Submitted: 2010-05-20
• Study First Submitted QC: 2010-05-20
• Study First Posted: 2010-05-21
• Study Start: 2010-07
• Primary Completion: 2015-04
• Study Completion: 2015-04
• Status Verified: 2018-11
• Last Update Submitted: 2018-11-30
• Last Update Posted: 2018-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S pneumoniae from a normally sterile site in a member of the surveillance population.

Exclusion Criteria

None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of IPD in the NCKP healthcare system in children 6 weeks through 5 years of age (prior to the sixth birthday) during each of the 5 years following introduction of Prevnar 13.	5 years

Trial Locations

Locations (1)

Kaiser Permanente Vaccine Study Center; 🇺🇸 Oakland, California, United States